Business

Licensing agreement

Licensing agreement.

articleTristel PlcSeptember 18, 20095/company/tristel/news/licensing-agreement-8
Licensing agreement

About this update from Tristel Plc

[{"type":"text","content":"\n RNS Number : 2836Z Tristel PLC 18 September 2009  \n \nTRISTEL plc\n('Tristel' or 'the Company')\nAIM: TSTL\n\nLicensing agreement for the Americas, launch of China subsidiary and trading update\n\nLicensing agreement with The Clorox Company of the United States\n\nTristel plc ('Tristel'), the specialist infection and contamination control company, announces that it has licensed its proprietary chlorine dioxide chemistry to The Clorox Company ('Clorox'), a leading manufacturer and marketer of consumer products, including its namesake bleach.\n\nClorox, based in Oakland, California, is an S&P500 company (stock symbol CLX) with annual sales in excess of $5 billion and 8,300 employees worldwide. It manufactures products in more than 15 countries and markets them in more than 100 countries\n\nEstablishment of China subsidiary\n\nTristel also announces that its wholly-owned subsidiary Stella Performance has established Shanghai Stella Medical Equipment Co. Ltd ('SSM') in Shanghai, China. SSM is launching the Stella Endoscope Decontamination System into the Chinese market and is also in the process of obtaining regulatory approval for Tristel's disinfectant products.\n\nThe Stella Decontamination System combines the simplicity and economy of manual disinfection of medical instruments with the sophistication of automated processes, without requiring the substantial capital expenditure involved with automation.  \n\nSSM has entered into its first distribution agreement. Hangzhou Medicine & Medical Devices Co. Ltd has been appointed as the distributor for Stella's products throughout Zhejiang Province on the eastern seaboard of China. The province has a population of 47 million, the fourth highest GDP per capita of the Chinese provinces, and 354 tier 2 and 3 hospitals (tier 3 being the largest). The agreement establishes a minimum purchase commitment over the next three years for 240 Stella units with a value of RMB4.87 million (£440,000).  \n\nChina is the third largest and fastest growing medical device market in the world. In 2004 the China Federation of Industrial Economics estimated China's disinfectant industry to be worth US$835 million.\n\nTrading update\n\nSince the beginning of its financial year in July, Tri...

More updates from Tristel Plc